Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1

Abstract

The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of KRAS/TP53 co-mutation on ICB response. Our analysis reveals that KRAS/TP53 co-mutation is associated with favorable ICB outcomes, a phenotype orchestrated by secreted phosphoprotein 1 (SPP1). Mechanistically, mutant p53 and KRAS exert opposing effects on SPP1. Mutant p53 synergizes with transcription factor FOXA1 to repress SPP1 transcription, whereas KRAS activates the mitogen-activated protein kinase (MAPK)–extracellular signal–regulated kinase (ERK)–signal transducer and activator of transcription 1 (STAT1) axis to up-regulate SPP1. Consequently, reduced SPP1 level in KRAS/TP53 co-mutant LUAD impairs myeloid-derived suppressor cell (MDSC) recruitment and increases CD8+ T cell infiltration. Notably, SPP1 blockade synergizes with anti–programmed death-1 (PD-1) therapy to suppress tumor growth in KRAS-mutant xenograft models. Collectively, we delineate a mutant p53–FOXA1–SPP1 regulatory axis that modulates ICB susceptibility and unveil a synergistic combination therapy strategy.